Skip to main content
. Author manuscript; available in PMC: 2021 Jul 23.
Published in final edited form as: Genet Med. 2021 Mar 29;23(7):1281–1287. doi: 10.1038/s41436-021-01134-9

Figure 1: Patients with a MYBPC3 VUS identified as deleterious by STRUM (STRUM +) are associated with an increased risk for adverse HCM-related outcomes.

Figure 1:

Selection within ShaRe of patients with HCM carrying a single MYBPC3 missense VUS is shown on the left. 105 patients carry a single MYBPC3 missense VUS, covering 77 distinct MYBPC3 VUSs. Kaplan Meier curves, median event free survival (years), and hazard ratio with corresponding 95% CI reveal that patients carrying a STRUM+ MYBPC3 VUS (red) exhibited a higher rate of adverse HCM-related outcomes (Overall Composite) compared to patients carrying a STRUM- variant (black).